LAMC2 is a potential prognostic biomarker for cholangiocarcinoma

Cholangiocarcinoma is a common malignancy with increasing incidence worldwide. Most patients are diag‑ nosed at the advanced stage with poor survival rate. Laminin subunit γ2 (LAMC2) is a heparin binding‑associated gene involved in tumorigenesis and has been implicated in the prognosis of various types of cancers. However, it is unclear whether expression of LAMC2 is associated with the clinical outcome of patients with cholangiocarcinoma. In the present study, the role and prognostic value of LAMC2 expression in patients with cholangiocarcinoma was investigated. Clinical information and pathological characteristics were analyzed and the association between LAMC2 expression and clinical characteristics, pathological findings and patient outcomes, including metastasis‑free and disease‑specific survival, were investigated. Data from 182 patients with cholangiocarcinoma were evaluated. High LAMC2 expression was associated with higher tumor stage (P<0.001), large duct type (P=0.024) and poor histological grade (P=0.002). Kaplan‑Meier anal‑ ysis showed high LAMC2 expression was associated with lower overall (P=0.003), disease‑specific (P=0.0025), local recurrence‑free (P<0.0001) and metastasis‑free survival (P<0.0001). Moreover, multivariate analysis demonstrated that increased LAMC2 expression was a significant predic‑ tive risk factor for overall [hazard ratio (HR) 1.713; P=0.034], disease‑specific (HR 2.011; P=0.039), local recurrence‑free (HR 2.721; P<0.001) and metastasis‑free survival (HR 3.117; P<0.001). Gene enrichment analysis using Gene Ontology showed that terms associated with LAMC2 upregula‑ tion were ‘regulation of platelet‑derived growth factor receptor‑βsignaling pathway’ and ‘platelet‑derived growth factor receptor‑β signaling pathway’. The present study indi‑ cated that LAMC2 was upregulated in cholangiocarcinoma tumor tissue and had an inverse association with overall, disease‑specific, local recurrence‑free and metastasis‑free survival in patients with cholangiocarcinoma. These results suggested that LAMC2 may serve as a potential biomarker for cholangiocarcinoma.